Report Overview

The US Prostate Cancer drugs market size is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.

The Prostate cancer market has a high demand for novel drugs that concentrate on unmet needs, such as improved survival time, less toxicity, better progression-free survival, improved effectiveness, and lesser cost. Prostate cancer is a progression of cancer in the prostate, a gland present in the male reproductive system. The cancer cells might reach the other parts of the body, viz. the bones and lymph nodes from the prostate. In the later stages of cancer, it can cause difficulty in urination, blood in the urine, etc. Prostate cancer is most of the time diagnosed by biopsy.



Market Drivers

There are factors such as a growing number of novel drugs expected to get launched in the short-term future and rising old-age male population are driving the growth of the market. Altering lifestyle, technological advancements in researching for new techniques to fight prostate cancer, increase in the funding in both the public and private sectors in the field of drug advancement are some of the key reasons driving the growth of the US prostate cancer market. The prostate cancer market is further anticipated to expand during the forecast period owing to growth opportunities such as untapped market potential due to unmet requirements of medical treatment, growing awareness among people, and advancements in the healthcare field. Further, patent expiration of significant drugs like Zytiga is likely to provide lucrative opportunities during the forecast period.